534 related articles for article (PubMed ID: 28506291)
1. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
2. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Özgör L; Brandl C; Shock A; Nitschke L
Eur J Immunol; 2016 Sep; 46(9):2260-72. PubMed ID: 27352780
[TBL] [Abstract][Full Text] [Related]
3. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Sieger N; Fleischer SJ; Mei HE; Reiter K; Shock A; Burmester GR; Daridon C; Dörner T
Arthritis Rheum; 2013 Mar; 65(3):770-9. PubMed ID: 23233360
[TBL] [Abstract][Full Text] [Related]
4. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
[TBL] [Abstract][Full Text] [Related]
5. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
6. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
7. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
8. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Fleischer SJ; Daridon C; Fleischer V; Lipsky PE; Dörner T
Arthritis Rheumatol; 2016 May; 68(5):1210-21. PubMed ID: 26713408
[TBL] [Abstract][Full Text] [Related]
10. CD22 and autoimmune disease.
Dörner T; Shock A; Smith KG
Int Rev Immunol; 2012 Oct; 31(5):363-78. PubMed ID: 23083346
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 7 cooperates with IL-4 in activated B cells through antigen receptor or CD38 and induces class switch recombination and IgG1 production.
Tsukamoto Y; Nagai Y; Kariyone A; Shibata T; Kaisho T; Akira S; Miyake K; Takatsu K
Mol Immunol; 2009 Apr; 46(7):1278-88. PubMed ID: 19157556
[TBL] [Abstract][Full Text] [Related]
12. Epratuzumab for systemic lupus erythematosus.
Wallace DJ; Goldenberg DM
Lupus; 2013 Apr; 22(4):400-5. PubMed ID: 23553783
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls.
Jacobi AM; Goldenberg DM; Hiepe F; Radbruch A; Burmester GR; Dörner T
Ann Rheum Dis; 2008 Apr; 67(4):450-7. PubMed ID: 17673490
[TBL] [Abstract][Full Text] [Related]
14. B cell autophagy mediates TLR7-dependent autoimmunity and inflammation.
Weindel CG; Richey LJ; Bolland S; Mehta AJ; Kearney JF; Huber BT
Autophagy; 2015; 11(7):1010-24. PubMed ID: 26120731
[TBL] [Abstract][Full Text] [Related]
15. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
16. High
Wang T; Marken J; Chen J; Tran VB; Li QZ; Li M; Cerosaletti K; Elkon KB; Zeng X; Giltiay NV
Front Immunol; 2019; 10():1243. PubMed ID: 31231380
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Reprogramming Commits Differentiation of Human CD27
Torigoe M; Iwata S; Nakayamada S; Sakata K; Zhang M; Hajime M; Miyazaki Y; Narisawa M; Ishii K; Shibata H; Tanaka Y
J Immunol; 2017 Jul; 199(2):425-434. PubMed ID: 28626065
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
Tsuru T; Tanaka Y; Kishimoto M; Saito K; Yoshizawa S; Takasaki Y; Miyamura T; Niiro H; Morimoto S; Yamamoto J; Lledo-Garcia R; Shao J; Tatematsu S; Togo O; Koike T
Mod Rheumatol; 2016; 26(1):87-93. PubMed ID: 26382733
[TBL] [Abstract][Full Text] [Related]
19. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus.
Shirota Y; Yarboro C; Fischer R; Pham TH; Lipsky P; Illei GG
Ann Rheum Dis; 2013 Jan; 72(1):118-28. PubMed ID: 22858586
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
